Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Le Tourneau

Showing results (1-10 of 262) with videos related to

Pageof 27
Sort By:
Bulletin Du Cancer|May 5, 2011
[Prevention strategies for brain metastases from HER2-positive breast cancer]Christophe Le Tourneau
Annals of Translational Medicine|January 13, 2021
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancerEdith Borcoman, Christophe Le Tourneau
Chinese Clinical Oncology|March 3, 2019
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?Francesco Ricci, Christophe Le Tourneau
Future Oncology (London, England)|December 12, 2017
Precision medicine strategies in oncology: mixed approaches to matched therapiesEdith Borcoman, Christophe Le Tourneau
Therapeutic Advances in Medical Oncology|June 14, 2017
Pembrolizumab in cervical cancer: latest evidence and clinical usefulnessEdith Borcoman, Christophe Le Tourneau
La Revue Du Praticien|May 26, 2009
[Tumours of testis]Christophe Le Tourneau, Laurent Mignot
La Revue Du Praticien|April 6, 2006
[Testicular tumors]Christophe Le Tourneau, Laurent Mignot
Chinese Clinical Oncology|November 22, 2017
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?Francesco Ricci, Christophe Le Tourneau
Current Opinion in Oncology|July 2, 2016
Antibody drug conjugates: the future of chemotherapy?Edith Borcoman, Christophe Le Tourneau
Aging|October 27, 2016
Combinations of targeted therapies in human cancersDidier Decaudin, Christophe Le Tourneau
Pageof 27

Showing results (1-10 of 262) with videos related to

Sort By:
Pageof 27
Bulletin Du Cancer|May 5, 2011
[Prevention strategies for brain metastases from HER2-positive breast cancer]Christophe Le Tourneau
Annals of Translational Medicine|January 13, 2021
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancerEdith Borcoman, Christophe Le Tourneau
Chinese Clinical Oncology|March 3, 2019
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?Francesco Ricci, Christophe Le Tourneau
Future Oncology (London, England)|December 12, 2017
Precision medicine strategies in oncology: mixed approaches to matched therapiesEdith Borcoman, Christophe Le Tourneau
Therapeutic Advances in Medical Oncology|June 14, 2017
Pembrolizumab in cervical cancer: latest evidence and clinical usefulnessEdith Borcoman, Christophe Le Tourneau
La Revue Du Praticien|May 26, 2009
[Tumours of testis]Christophe Le Tourneau, Laurent Mignot
La Revue Du Praticien|April 6, 2006
[Testicular tumors]Christophe Le Tourneau, Laurent Mignot
Chinese Clinical Oncology|November 22, 2017
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence?Francesco Ricci, Christophe Le Tourneau
Current Opinion in Oncology|July 2, 2016
Antibody drug conjugates: the future of chemotherapy?Edith Borcoman, Christophe Le Tourneau
Aging|October 27, 2016
Combinations of targeted therapies in human cancersDidier Decaudin, Christophe Le Tourneau
Pageof 27